Skip to main content

Epilepsy: Pregnancy

Question for Department of Health and Social Care

UIN 138438, tabled on 15 January 2021

To ask the Secretary of State for Health and Social Care, with reference to the Commission on Human Medicines' review of the use of epilepsy medicines in pregnancy, published on 7 January 2021, whether the provisions of the Pregnancy Prevention Programme will be extended to include any other anti-epileptic drugs identified in posing a risk.

This answer is the replacement for a previous holding answer.

Answered on

21 January 2021

The Commission on Human Medicines’ review concluded that lamotrigine and levetiracetam are safer to use during pregnancy than other epilepsy medicines and that some of the other reviewed antiepileptic drugs may also be associated with harms to the child. Where the data support evidence of harm, neither the magnitude nor the nature of the risks observed with the reviewed epilepsy medicines are as severe as that associated with the use of valproate during pregnancy. A Pregnancy Prevention Programme therefore has not been recommended for any of the other reviewed epilepsy medicines at this time.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.